CDER New Drug Reviews Are At 80%-90% Of User Fee Goals, Jenkins Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Center for Drug Evaluation and Research's performance in reviewing applications for new drugs and biologics within the timelines specified by the Prescription Drug User Fee Act has slipped to 80 percent to 90 percent
You may also be interested in...
Running Late: FDA Review Timelines Lengthen For New Product Applications
FDA is missing more new drug review deadlines: at least seven in the first eight months of this year. The experiences of those delayed applications indicate some interesting ways to interpret what it means when a user fee date comes and goes without an FDA decision. One clear observation: the longer a sponsor has to wait after the user fee deadline, the worse the likely result
Running Late: FDA Review Timelines Lengthen For New Product Applications
FDA is missing more new drug review deadlines: at least seven in the first eight months of this year. The experiences of those delayed applications indicate some interesting ways to interpret what it means when a user fee date comes and goes without an FDA decision. One clear observation: the longer a sponsor has to wait after the user fee deadline, the worse the likely result
CDER Staffing Is Real Culprit Behind Missed User Fee Dates – FDA Official
SAN DIEGO - Even with its new, more aggressive hiring campaign, the Center for Drug Evaluation and Research will take up to a year or more to become fully staffed, a CDER official said June 22 at the Biotechnology Industry Organization annual conference